A Randomized, Double-Blind, Phase III Study to Evaluate Adjuvant cG250 [WX G250; Rencarex; Wilex] Treatment Versus Placebo in Patients With Clear Cell RCC [renal cell carcinoma] and High Risk of Recurrence.
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Girentuximab (Primary)
- Indications Renal cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms ARISER
- Sponsors Heidelberg Pharma AG
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG
- 01 Feb 2014 Results of an analysis that investigated the effects of obesity of treatment outcomes presented at the 2014 Genitourinary Cancers Symposium.
- 05 Jun 2013 Primary endpoint 'Overall-survival' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History